AKRO News and Press, Akero Therapeutics Inc. From 10/16/20

The European Medicines Agency ((EMA)) has granted Priority Medicines ((PRIME)) designation to Akero Therapeutics' (AKRO) efruxifermin ((EFX)), an investigational FGF21 analog for the treatment of non-alcoholic steatohepatitis ((NASH)).PRIME, akin to Breakthrough Therapy status in the U.S., pr...

Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH Designation highlights EFX's potential to treat NASH and its related comorbidities PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 16, 2020 S...

Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting® 2020 PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 2, 2020 SOUTH SAN FRANCISCO, Calif., Oct. 2, 2020 /PRN...

Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study PR Newswire SAN FRANCISCO, Sept. 30, 2020 SAN FRANCISCO , Sept. 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-me...

Akero Therapeutics to continue with mid stage Efruxifermin trial. BioMarin initiated mid stage study for BMN 307. BeyondSpring presents positive data for Plinabulin in preventing neutropenia. For further details see: Akero Continues Efruxifermin Trial, And Other News: Th...

Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 28, 2020 SOUTH SAN FRANCISCO, Calif. , Sept. 28, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clin...

Akero Therapeutics (AKRO) has received written guidance from the FDA that enables the company to implement a combined Phase 2b/3 study for its lead candidate efruxifermin ((EFX)) in NASH patients.Under the planned adaptive trial design, Akero will evaluate two EFX doses in a 24-week...

Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2020 /PRNewswire/ -...

Quick Take Metacrine ( MTCR ) intends to raise $85 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for NASH conditions. MTCR is entering Phase 2 trials and will have significant capital ...

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders...